REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-13. Anything still debated is marked as such rather than presented as settled.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
=== Carbon dioxide transport === CO2 is carried in blood in three different ways. (The exact percentages vary depending whether it is arterial or venous blood). Most of it (about 70%) is converted to bicarbonate ions HCO−3 by the enzyme carbonic anhydrase in the red blood cells by the reaction CO2 + H2O → H2CO3 → H+ + HCO−3; about 7% is dissolved in the plasma; and about 23% is bound to hemoglobin as carbamino compounds. Hemoglobin, the main oxygen-carrying molecule in red blood cells, carries both oxygen and carbon dioxide. However, the CO2 bound to hemoglobin does not bind to the same site as oxygen. Instead, it combines with the N-terminal groups on the four globin chains. However, because of allosteric effects on the hemoglobin molecule, the binding of CO2 decreases the amount of oxygen that is bound for a given partial pressure of oxygen. The decreased binding to carbon dioxide in the blood due to increased oxygen levels is known as the Haldane effect, and is important in the transport of carbon dioxide from the tissues to the lungs. A rise in the partial pressure of CO2 or a lower pH will cause offloading of oxygen from hemoglobin, which is known as the Bohr effect.
They are marketed to people as being safer than traditional cigarettes. They are also marketed to non-smokers. E-cigarette marketing is common. There are growing concerns that e-cigarette advertising campaigns unjustifiably focus on young adults, adolescents, and women. Large tobacco companies have greatly increased their marketing efforts. This marketing trend may expand the use of e-cigarettes and contribute to re-glamorizing smoking. Some companies may use e-cigarette advertising to advocate smoking, deliberately, or inadvertently, is an area of concern. The e-cigarette companies have expanded using aggressive marketing messages like those used to promote cigarettes in the 1950s and 1960s. E-cigarette companies are using methods that were once used by the tobacco industry to persuade young people to start using cigarettes. E-cigarettes are promoted to a certain extent to forge a vaping culture that entices non-smokers. Themes in e-cigarette marketing, including sexual content and customer satisfaction, are parallel to themes and techniques that are appealing to young people and young adults in traditional cigarette advertising and promotion. A 2017 review found "The tobacco industry sees a future where ENDS accompany and perpetuate, rather than supplant, tobacco use, especially targeting the youth." E-cigarettes and nicotine are regularly promoted as safe and even healthy in the media and on brand websites, which is an area of concern.
Drug delivery involves various methods and technologies designed to transport pharmaceutical compounds to their target sites helping therapeutic effect. It involves principles related to drug preparation, route of administration, site-specific targeting, metabolism, and toxicity all aimed to optimize efficacy and safety, while improving patient convenience and compliance. A key goal of drug delivery is to modify a drug's pharmacokinetics and specificity by combining it with different excipients, drug carriers, and medical devices designed to control its distribution and activity in the body. Enhancing bioavailability and prolonging duration of action are essential strategies for improving therapeutic outcomes, particularly in chronic disease management. Additionally, some research emphasizes on improving safety for the individuals administering the medication. For example, microneedle patches have been developed for vaccines and drug delivery to minimize the risk of needlestick injuries. Drug delivery is closely linked with dosage form and route of administration, the latter of which is sometimes considered to be part of the definition. Although the terms are often used interchangeably, they represent distinct concepts. The route of administration refers specifically to the path by which a drug enters the body, such as oral, parenteral, or transdermal. In contrast, the dosage form refers to the physical form in which the drug is manufactured and delivered, such as tablets, capsules, patches, inhalers or injectable solutions.
Sources: en.wikipedia.org
Based on animal research, it was initially thought that bicalutamide was unable to cross the blood–brain barrier into the central nervous system and hence would be a peripherally-selective antiandrogen in humans. This conclusion was drawn from the finding that bicalutamide reportedly does not increase LH or testosterone levels in multiple tested animal species, including rats and dogs. AR antagonists like flutamide normally do this by blocking ARs in the pituitary gland and hypothalamus in the brain and thereby disinhibiting the HPG axis. The notion that bicalutamide does not cross the blood–brain barrier is in accordance with rodent tissue distribution studies, which have found low levels of bicalutamide in the hypothalamus and cerebral cortex relative to most peripheral tissues and the pituitary gland (a part of the brain that is outside of the blood–brain barrier). In spite of the preceding studies however, other rodent studies have contradicted these results and found that bicalutamide does significantly and dose-dependently increase LH and testosterone levels, and in some studies to a similar extent as flutamide. In any case, in humans, bicalutamide has consistently been found to increase LH and testosterone levels, and to a comparable extent relative to flutamide and nilutamide. This occurs to a significant extent at even a very low dosage of 10 mg/day bicalutamide.
The removal of the state-affiliated label followed a change in Twitter's algorithm, in which restrictions on accounts belonging to Russian state media were lifted. RT editor-in-chief Margarita Simonyan congratulated Musk on lifting the restrictions on her account.
== Benefits == Financial help is given to build fishing infrastructure like harbors, fish landing areas, fish markets, fish feed facilities, fish seed farms, and fish processing facilities. Financial help for fish farmers: The program offers money to fish farmers for building ponds, cages, hatcheries, and nurseries, and for setting up aeration systems and other equipment. The program provides money to support the management of fisheries by using scientific methods, making management plans, and creating information systems. Fish farmers can apply for a subsidy linked to credit, which aims to encourage them to start fish farms as a business. Support for marketing and exporting fish products: The program provides money to set up cold chains, fish processing facilities, and packaging facilities to help export fish products.
== Publications == J. Kopeček, J. Yang, "Polymer Nanomedicines". Advanced Drug Delivery Reviews 156, 40–66 (2020) L. Li, Y. Li, C.-H. Yang, D.C. Radford, J. Wang, M. Janát-Amsbury, J. Kopeček, J. Yang, "Inhibition of Immunosuppresive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking". Advanced Functional Materials 30:1908961 (2020) L. Li, J. Wang, Y. Li, D.C. Radford, J. Yang, J. Kopeček, "Broadening and Enhancing Functions of Antibodies by Self-Assembling Multimerization at Cell Surface". ACS Nano 13, 11422–11432 (2019) J. Yang, L. Li, J. Kopeček, "Biorecognition: A Key to Drug-free Macromolecular Therapeutics". Biomaterials 190–191, 11–23 (2019) J. Wang, L. Li, J. Yang, P.M. Clair, M. Glenn, D.M. Stephens, D.C. Radford, K.M. Kosak, M.W. Deininger, P.J. Shami, J. Kopeček, "Drug-free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction by Pretreatment with Gemcitabine". Nanomedicine: Nanotechnology, Biology and Medicine 16, 217–225 (2019). J. Yang, R. Zhang, H. Pan, Y. Li, Y. Fang, L. Zhang, J. Kopeček, "Backbone Degradable HPMA Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts". Molecular Pharmaceutics 14, 1384–1394 (2017) J.M. Hartley, T.-W. Chu, E.M. Peterson, R. Zhang, J. Yang, J. Harris, J.
Sources: en.wikipedia.org
== Bibliography == Atwood, David A. (2013). Radionuclides in the Environment. John Wiley and Sons. ISBN 978-1-118-63269-7. Emsley, John (2011). Nature's Building Blocks: An A-Z Guide to the Elements. New York: Oxford University Press, USA. ISBN 978-0-199-60563-7. Hoffman, Klaus (2001). Otto Hahn: Achievement and Responsibility. Springer. Bibcode:2002ohar.book.....H. ISBN 978-0-387-95057-0. Lemire, Robert J. (2001). Chemical Thermodynamics of Neptunium and Plutonium. Amsterdam: Elsevier. ISBN 978-0-444-50379-4. Rhodes, Richard (2012). The Making of the Atomic Bomb (25th Anniversary ed.). New York: Simon & Schuster. ISBN 978-1-451-67761-4. Yoshida, Zenko; Johnson, Stephen G.; Kimura, Takaumi; Krsul, John R. (2006). "Neptunium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements (PDF). Vol. 3 (3rd ed.). Dordrecht, the Netherlands: Springer. pp. 699–812. doi:10.1007/1-4020-3598-5_6. ISBN 978-1-4020-3555-5. Archived from the original (PDF) on January 17, 2018.
Exenatide, sold under the brand name Byetta among others, is a medication used to treat type 2 diabetes. It is used together with diet, exercise, and potentially other antidiabetic medication. It is a treatment option after metformin and sulfonylureas. It is given by injection under the skin. Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection. Other serious side effects may include medullary thyroid cancer, angioedema, pancreatitis, and kidney injury. Use in pregnancy and breastfeeding is of unclear safety. Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release. Exenatide was approved for medical use in the United States in 2005. In 2019, it was the 312th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
There is great variation in the carbon isotope composition of amino acids within a single organism. In cyanobacteria, Macko et al. observed a ~30‰ range in δ13C values amongst the amino acids. Amino acids produced from the same precursors also had widely varying compositions. It is difficult to explain these trends because of limited data on the kinetic isotope effects associated with reactions that synthesize amino acid carbon skeletons. Nevertheless, some insights can be gained by applying the logic above to the reaction networks responsible for amino acid biosynthesis. Consider the amino acids synthesized from pyruvate. Pyruvate is produced during glycolysis and can be decarboxylated by pyruvate dehydrogenase to generate acetyl groups. These acetyl groups enter the citric acid cycle as acetyl-CoA or can be used to synthesize lipids. There is a large kinetic isotope effect associated with this reaction, so the remaining pyruvate pool becomes enriched in 13C relative to the acetyl groups. This enriched pyruvate can be transaminated to produce alanine. In the experiments by Macko et al., alanine indeed had a δ13C value slightly higher than that of cyanobacterial photosynthate. Valine is synthesized by the addition of a 13C depleted acetyl group to pyruvate. Consistent with this mechanism, Takano et al. found valine to be depleted in 13C relative to alanine in anaerobic methanotrophic archaea. However, in cyanobacteria, Macko et al. observed a higher δ13C value for valine than alanine.
Since its founding in 1517 on the orders of François I, Le Havre has continued to grow: today it measures 27 km (17 mi) from east to west, about 5 km (3 mi) from north to south with an area of 10,000 hectares (24,711 acres). The last big project called Port 2000 increased the handling capacity for containers. The port provides 16,000 direct jobs to the Le Havre region, to which must be added indirect jobs in industry and transport. With approximately 3,000 employees in 2006, the activities of distribution and warehousing provide more jobs, followed by road transport (2,420 jobs) and handling (2,319 jobs). In 2011, 715,279 passengers passed through the port of Le Havre and there were 95 visits by cruise ships carrying 185,000 passengers. The port expects 110 cruise ship calls in 2012. Created in 1934, the leisure boat harbour of Le Havre is located to the west and is the largest French boat harbour in the Channel with a capacity of 1,160 moorings. Finally, there is a small fishing port in the Saint-François district and a Hawker centre.
Once released into the air, VOCs can undergo reactions with ozone and hydroxyl radicals to produce other VOCs, such as formaldehyde. Health effects include eye, nose, and throat irritation; headaches, loss of coordination, nausea; and damage to the liver, kidney, and central nervous system. Testing emissions from building materials used indoors has become increasingly common for floor coverings, paints, and many other important indoor building materials and finishes. Indoor materials such as gypsum boards or carpet act as VOC 'sinks', by trapping VOC vapors for extended periods of time, and releasing them by outgassing. The VOCs can also undergo transformation at the surface through interaction with ozone. In both cases, these delayed emissions can result in chronic and low-level exposures to VOCs. Several initiatives aim to reduce indoor air contamination by limiting VOC emissions from products. There are regulations in France and in Germany, and numerous voluntary ecolabels and rating systems containing low VOC emissions criteria such as EMICODE, M1, Blue Angel and Indoor Air Comfort in Europe, as well as California Standard CDPH Section 01350 and several others in the US. Due to these initiatives an increasing number of low-emitting products became available to purchase.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.